Product Data Sheet

Product Data Sheet		
Product Number	D004	
Revision Number	RN3.1	
Product Name	1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium trifluorosulfonic acid salt	
Synonym	"L-683.685"; 1,3-Dimethyl-2-(2-oxopropylthio)-4,5-diphenyl-1H-imidazol-3-ium trifluoromethanesulfonate	
Application	Inhibitior for transglutaminase, cell-permeable [3]	
Efficacy	The molecule was developed to block coagulation factor XIIIa, however the compound inhibits tissue transglutaminase as well. Both enzymes are inhibited with an IC ₅₀ of about 0.35 μ M.	
Molecular Formula	$C_{21}H_{21}F_{3}N_{2}O_{4}S_{2}$ (free cation: $C_{20}H_{21}N_{2}OS^{+}$)	
Molecular Weight	486.53 (free cation: 337.46)	
Chemical Structure	$ \begin{array}{c} & F_{3}C-SO_{3}^{-} \\ & N \\ & N \\ & N \\ & N \\ & & \\ $	
Purity by HPLC	>90 % (214 nm)	
Solubility	Pre-dissolve e.g. 2.02 mg in 207.6 μ l DMSO to obtain a 20 mM stock solution - dilute 20 μ l of that stock solution with 980 μ l buffer (e.g. 50 mM TRIS-HCI, pH 7.5) to obtain a 400 μ M solution	
Appearance	Off white solid	
Storage	Store at -20°C, desiccate	
Related Products	A101 Abz-NE(CAD-DNP)EQVSPLTLLK-OH A102 Abz-APE(CAD-DNP)QEA-OH T006 Guinea pig liver transglutaminase T002 Human tissue transglutaminase (hTG2, recombinant in <i>E. coli</i>) T007 Coagulation factor XIII purified from human plasma (pFXIII, A ₂ B ₂) T027 Human blood coagulation Factor XIII, recombinant	
Reference(s)	[1] Lorand L. <i>et al. Exp. Eye Res</i> . 1998 , <i>66</i> , 531. [2] Barsigian C. <i>et al. J. Biol. Chem.</i> 1991 , <i>266</i> , 22501. [3] Basso, M. et al. J. Neurosci. 2012, 32, 6561.	
Release date	23 March 2022	
NOTE	INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.	

Product Number	D004
Revision Number	RN3.1



APPLICATION

INHIBITION OF PURIFIED TISSUE-TGase (HIS₆-rhTG2)

1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium, trifluorosulfonic acid salt is a potent, active site directed inhibitor. The reaction results in an acetonylation of active site cysteine. The inhibition parameters were obtained by progress curve analysis using a continuous assay after preincuabation with the inhibitor (Fig. 1a and 1b).



Inhibition of His6-rhTG2 by preincubation with 1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium, trifluorosulfonicacid salt.

Fig.1a: 10 μ g His₆-rhTG2 were preincubated with 0.1-5 μ M 1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium, trifluorosulfonic acid salt, containing 10 mM CaCl₂. After 5 min at 37°C, remaining activity was measured continuously using Abz-APE(CAD-DNP)QEA-OH as substrate. The substrate carries a fluorescent dye and a suitable quencher. The fluorescence increases upon transglutaminase-catalysed removal of the quencher molecule and can be measured online (37°C, ex. wavelength = 313 nm, em. wavelength = 418 nm). The activity is determined by the difference of fluorescence intensity between 5 and 10 min.

Product Data Sheet

Product Number	D004
Revision Number	RN3.1



Inhibition of His₆-hTG2 by preincubation with

1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium, trifluorosulfonicacid salt.



Fig.1b: Transglutaminase activity vs. inhibitor concentration. Illustration results from online-measurements, displayed in Fig.1a. Activity of sample in the absence of inhibitor was taken as 100%, the other values were compared with this value.